Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok2. fázis

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

A legfontosabb adatok

Hol
Ankeny, Ann Arbor, Appleton, Ashland, Beverly Hills, Brighton, Burlington, Canton, Cedar Rapids, Charleston, Chelsea, Chicago, City of Saint Peters, Clive, Creve Coeur, Crown Point, Danville, Deer River, Des Moines, Duarte, Duluth, Dyer, Eau Claire, Effingham, Flint, Fort Lauderdale, Germantown, Grafton, Green Bay, Hibbing, Hobart, Houston, Huntington Beach, Indianapolis, Jackson, Kenosha, La Crosse, Lancaster, Lansing, Livonia, Long Beach, Los Angeles, Marinette, Marshfield, Mattoon, Miami Beach, Milwaukee, Minocqua, Munster, New Lenox, New York, Newberg, Newport Beach, Oklahoma City, Oregon City, Orland Park, Oshkosh, Pontiac, Portland, Racine, Rice Lake, Richmond, Rochester, Salt Lake City, San Antonio, Sandstone, Sheboygan, Shiloh, South Pasadena, St Louis, Stevens Point, Summit, Torrance, Tucson, Two Rivers, Upland, Urbana, Valparaiso, Virginia, Wauwatosa, Webster, West Allis, Weston és Ypsilanti (Egyesült Államok)Mind a 104 helyszín megnézése
Fázis
2. fázis

AI-kivonat: kiket keres a vizsgálat

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek nagy B-sejtes lymphomájuk kiújult vagy nem reagált a korábbi kezelésre, és nem kaphatnak vagy nem kérnek őssejt-átültetést.

Életkor
18 éves vagy idősebb
Nem
Mindkét nem részt vehet
A betegség stádiuma
Kiújult vagy a kezelésre nem reagáló nagy B-sejtes lymphoma, ide értve a 3B fokozatú follicularis lymphomát, az átalakult lymphomát és a magas fokozatú B-sejtes lymphomát. A regisztráció előtti 28 napon belüli képalkotó vizsgálaton mérhető betegségnek kell látszania.
Korábbi kezelés
1-5 korábbi szisztémás kezelés, köztük egy többszereses kezelés agresszív lymphomára. A korábbi kezelésnek be kell fejeződnie, és a résztvevőnek ki kell heverni azt. Korábbi tafasitamab, lenalidomid, BTK-gátló vagy tazemetostat nem megengedett.
Biomarker vagy leletérték
A lymphomának csíracentrum típusúnak kell lennie a kórbonctani lelet szerint (Hans-féle immunhisztokémiai vizsgálat: CD10, BCL6, MUM1).

A részvétel fő kizáró okai

  • Központi idegrendszeri lymphomás érintettség
  • A vizsgáló szerint a személy autológ őssejt-átültetésre jelölt, és nem utasította el azt
  • Ismert allergia a tafasitamabra, lenalidomidra, tazemetostatra vagy zanubrutinibre
  • Terhesség vagy szoptatás
  • Bizonyos, a CYP3A enzimet érintő gyógyszerek vagy direkt K-vitamin-gátlók szedése

Gépi kiolvasás: 2026. november 12.

Helyszínek itt: Egyesült Államok

  • UI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny, Egyesült ÁllamokContact: Katarina GasicNo longer taking part
  • Trinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • ThedaCare Regional Cancer CenterAppleton, Egyesült ÁllamokContact: Yazhini Vallatharasu (principal investigator)Résztvevőt keres
  • Duluth Clinic AshlandAshland, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Tower Cancer Research FoundationBeverly Hills, Egyesült ÁllamokContact: Akil A. Merchant (principal investigator)Résztvevőt keres
  • Trinity Health IHA Medical Group Hematology Oncology - BrightonBrighton, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Trinity Health Medical Center - BrightonBrighton, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Aurora Cancer Care-Southern Lakes VLCCBurlington, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Trinity Health IHA Medical Group Hematology Oncology - CantonCanton, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Trinity Health Medical Center - CantonCanton, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Mercy HospitalCedar Rapids, Egyesült ÁllamokContact: Deborah W. Wilbur (principal investigator)Résztvevőt keres
  • Oncology Associates at Mercy Medical CenterCedar Rapids, Egyesült ÁllamokContact: Deborah W. Wilbur (principal investigator)Résztvevőt keres
  • Medical University of South CarolinaCharleston, Egyesült ÁllamokContact: Brian T. Hess (principal investigator)Résztvevőt keres
  • Chelsea HospitalChelsea, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • University of Chicago Comprehensive Cancer CenterChicago, Egyesült ÁllamokContact: Justin P. Kline (principal investigator)Résztvevőt keres
  • University of IllinoisChicago, Egyesült ÁllamokContact: Paul G. Rubinstein (principal investigator)Résztvevőt keres
  • Siteman Cancer Center at Saint Peters HospitalCity of Saint Peters, Egyesült ÁllamokContact: Nancy L. Bartlett (principal investigator)Résztvevőt keres
  • UI Health Care Mission Cancer and Blood - West Des Moines ClinicClive, Egyesült ÁllamokContact: Katarina GasicNo longer taking part
  • Siteman Cancer Center at West County HospitalCreve Coeur, Egyesült ÁllamokContact: Nancy L. Bartlett (principal investigator)Résztvevőt keres
  • Northwest Cancer Center - Main CampusCrown Point, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Carle at The RiverfrontDanville, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Essentia Health - Deer River ClinicDeer River, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Mercy Medical Center - Des MoinesDes Moines, Egyesült ÁllamokContact: Richard L. Deming (principal investigator)Résztvevőt keres
  • UI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines, Egyesült ÁllamokContact: Katarina GasicNo longer taking part
  • City of Hope Comprehensive Cancer CenterDuarte, Egyesült ÁllamokContact: Alexey V. Danilov (principal investigator)Résztvevőt keres
  • Essentia Health Cancer CenterDuluth, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Northwest Oncology LLCDyer, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Marshfield Medical Center-EC Cancer CenterEau Claire, Egyesült ÁllamokContact: Dean A. Delmastro (principal investigator)Résztvevőt keres
  • Carle Physician Group-EffinghamEffingham, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Cancer Hematology Centers - FlintFlint, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Genesys Hurley Cancer InstituteFlint, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Hurley Medical CenterFlint, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Genesee Hematology Oncology PCFlint, Egyesült ÁllamokContact: Katarina GasicNo longer taking part
  • Holy Cross HospitalFort Lauderdale, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Aurora Health Care Germantown Health CenterGermantown, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Aurora Cancer Care-GraftonGrafton, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Aurora BayCare Medical CenterGreen Bay, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Essentia Health Hibbing ClinicHibbing, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Northwest Cancer Center - HobartHobart, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Saint Mary Medical CenterHobart, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston, Egyesült ÁllamokContact: Akiva Diamond (principal investigator)Résztvevőt keres
  • Ben Taub General HospitalHouston, Egyesült ÁllamokContact: Akiva Diamond (principal investigator)Résztvevőt keres
  • City of Hope SeacliffHuntington Beach, Egyesült ÁllamokContact: Alexey V. Danilov (principal investigator)Résztvevőt keres
  • Saint Catherine HospitalIndianapolis, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • University of Mississippi Medical CenterJackson, Egyesült ÁllamokContact: Carrie K. Wynn (principal investigator)Résztvevőt keres
  • Aurora Cancer Care-Kenosha SouthKenosha, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Gundersen Lutheran Medical CenterLa Crosse, Egyesült ÁllamokContact: David E. Marinier (principal investigator)Résztvevőt keres
  • City of Hope Antelope ValleyLancaster, Egyesült ÁllamokContact: Alexey V. Danilov (principal investigator)Résztvevőt keres
  • University of Michigan Health - Sparrow LansingLansing, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Trinity Health Saint Mary Mercy Livonia HospitalLivonia, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • City of Hope at Long Beach ElmLong Beach, Egyesült ÁllamokContact: Alexey V. Danilov (principal investigator)Résztvevőt keres
  • Cedars-Sinai Medical CenterLos Angeles, Egyesült ÁllamokContact: Akil A. Merchant (principal investigator)Résztvevőt keres
  • Aurora Bay Area Medical Group-MarinetteMarinette, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Marshfield Medical Center-MarshfieldMarshfield, Egyesült ÁllamokContact: Dean A. Delmastro (principal investigator)Résztvevőt keres
  • Carle Physician Group-Mattoon/CharlestonMattoon, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Mount Sinai Medical CenterMiami Beach, Egyesült ÁllamokContact: Katarina GasicNo longer taking part
  • Aurora Cancer Care-MilwaukeeMilwaukee, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Aurora Saint Luke's Medical CenterMilwaukee, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Aurora Sinai Medical CenterMilwaukee, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Marshfield Medical Center - MinocquaMinocqua, Egyesült ÁllamokContact: Dean A. Delmastro (principal investigator)Résztvevőt keres
  • The Community HospitalMunster, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Women's Diagnostic Center - MunsterMunster, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • UC Comprehensive Cancer Center at Silver CrossNew Lenox, Egyesült ÁllamokContact: Justin P. Kline (principal investigator)Résztvevőt keres
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York, Egyesült ÁllamokContact: Jennifer E. Amengual (principal investigator)Résztvevőt keres
  • Providence Newberg Medical CenterNewberg, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • City of Hope Newport BeachNewport Beach, Egyesült ÁllamokContact: Alexey V. Danilov (principal investigator)Résztvevőt keres
  • University of Oklahoma Health Sciences CenterOklahoma City, Egyesült ÁllamokContact: Taha Al-Juhaishi (principal investigator)Résztvevőt keres
  • Providence Willamette Falls Medical CenterOregon City, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • University of Chicago Medicine-Orland ParkOrland Park, Egyesült ÁllamokContact: Justin P. Kline (principal investigator)Résztvevőt keres
  • Vince Lombardi Cancer Clinic - OshkoshOshkosh, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Trinity Health Saint Joseph Mercy Oakland HospitalPontiac, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Providence Portland Medical CenterPortland, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Providence Saint Vincent Medical CenterPortland, Egyesült ÁllamokContact: Charles W. Drescher (principal investigator)Résztvevőt keres
  • Aurora Cancer Care-RacineRacine, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Marshfield Medical Center-Rice LakeRice Lake, Egyesült ÁllamokContact: Dean A. Delmastro (principal investigator)Résztvevőt keres
  • VCU Massey Cancer Center at Stony PointRichmond, Egyesült ÁllamokContact: Victor Y. Yazbeck (principal investigator)Résztvevőt keres
  • VCU Massey Comprehensive Cancer CenterRichmond, Egyesült ÁllamokContact: Victor Y. Yazbeck (principal investigator)Résztvevőt keres
  • University of RochesterRochester, Egyesült ÁllamokContact: Patrick M. Reagan (principal investigator)Résztvevőt keres
  • Huntsman Cancer Institute/University of UtahSalt Lake City, Egyesült ÁllamokContact: Allison Bock (principal investigator)Résztvevőt keres
  • University of Texas Health Science Center at San AntonioSan Antonio, Egyesült ÁllamokContact: Adolfo E. Diaz Duque (principal investigator)Résztvevőt keres
  • Essentia Health SandstoneSandstone, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Vince Lombardi Cancer Clinic-SheboyganSheboygan, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Memorial Hospital EastShiloh, Egyesült ÁllamokContact: Nancy L. Bartlett (principal investigator)Résztvevőt keres
  • City of Hope South PasadenaSouth Pasadena, Egyesült ÁllamokContact: Alexey V. Danilov (principal investigator)Résztvevőt keres
  • Siteman Cancer Center at Christian HospitalSt Louis, Egyesült ÁllamokContact: Nancy L. Bartlett (principal investigator)Résztvevőt keres
  • Siteman Cancer Center-South CountySt Louis, Egyesült ÁllamokContact: Nancy L. Bartlett (principal investigator)Résztvevőt keres
  • Washington University School of MedicineSt Louis, Egyesült ÁllamokContact: Nancy L. Bartlett (principal investigator)Résztvevőt keres
  • Marshfield Medical Center-River Region at Stevens PointStevens Point, Egyesült ÁllamokContact: Dean A. Delmastro (principal investigator)Résztvevőt keres
  • Aurora Medical Center in SummitSummit, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • City of Hope South BayTorrance, Egyesült ÁllamokContact: Alexey V. Danilov (principal investigator)Résztvevőt keres
  • Banner University Medical Center - TucsonTucson, Egyesült ÁllamokContact: Krishna Rekha Moturi (principal investigator)Résztvevőt keres
  • University of Arizona Cancer Center-North CampusTucson, Egyesült ÁllamokContact: Krishna Rekha Moturi (principal investigator)Résztvevőt keres
  • Vince Lombardi Cancer Clinic-Two RiversTwo Rivers, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • City of Hope UplandUpland, Egyesült ÁllamokContact: Alexey V. Danilov (principal investigator)Résztvevőt keres
  • Carle Cancer CenterUrbana, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Northwest Cancer Center - ValparaisoValparaiso, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Essentia Health Virginia ClinicVirginia, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Aurora Cancer Care-Milwaukee WestWauwatosa, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Wilmot Cancer Institute at WebsterWebster, Egyesült ÁllamokContact: Patrick M. Reagan (principal investigator)Résztvevőt keres
  • Aurora West Allis Medical CenterWest Allis, Egyesült ÁllamokContact: Thomas J. Saphner (principal investigator)Résztvevőt keres
  • Marshfield Medical Center - WestonWeston, Egyesült ÁllamokContact: Dean A. Delmastro (principal investigator)Résztvevőt keres
  • Huron Gastroenterology PCYpsilanti, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres
  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti, Egyesült ÁllamokContact: Tareq Al baghdadi (principal investigator)Résztvevőt keres

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

A vizsgálat adatai

Ki végzi
SWOG Cancer Research Network
Azonosító
NCT05890352
A regiszteradat frissítve
2026. október 28.
Eredeti leírás
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The addition of tazemetostat or zanubrutinib to tafasitamab and lenalidomide may be able to shrink the cancer or extend the time without cancer symptoms coming back.A teljes eredeti leírásKevesebb

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-Cell Lymphoma

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The addition of tazemetostat or zanubrutinib to tafasitamab and lenalidomide may be able to shrink the cancer or extend the time without cancer symptoms coming back.

Bevonási feltételek: Participants must have:; Histologically confirmed relapsed/refractory LBCL as outlined by the World Health Organization (WHO) guidelines; Follicular lymphoma, grade 3B; Transformed lymphoma; High grade B-cell lymphoma with or without MYC, BCL2 and/or BCL6 rearrangements; Participants must have staging imaging performed within 28 days prior to registration, as follows. Positron emission tomography (PET)-computed tomography (CT) baseline scans are strongly preferred; diagnostic quality magnetic resonance imaging (MRI), contrast-enhanced CT, or contrast-enhanced MRI scans are also acceptable if PET-CT is not feasible at baseline. Note: PET-CT will be required at end of treatment (EOT) and progression for response assessment. All measurable lesions (longest diameter >= 1.5 cm) must be assessed within 28 days prior to registration. Tests to assess non-measurable disease must be performed within 28 days prior to registration. All disease must be documented on the Baseline Tumor Assessment Form; Participants must have cell of origin (COO) determination of germinal center (GC)(GCB or non-GC GCB) of LBCL based on Hans immunohistochemistry algorithm (CD10, BCL6, MUM1) as noted on pathology report; Participants must have had 1-5 prior systemic treatment regimens including one systemic multiagent regimen for aggressive lymphoma; Participants who have received prior systemic therapy must have completed their last treatment prior to registration. Participants must have recovered from previous therapy; Steroid use for the control of non-Hodgkin lymphoma symptoms is allowable, but must be discontinued prior to Cycle 1, Day 1; Participant must be >= 18 years old; Participant must have Zubrod Performance Status of 0-3; Participant must have a complete medical history and physical exam within 28 days prior to registration; Absolute neutrophil count >= 1.0 x 10\^3/uL (within 28 days prior to registration); If there is documented lymphomatous involvement of the bone marrow as assessed by bone marrow biopsy within 90 days prior to registration, participants must have: Absolute neutrophil count (ANC) >= 0.75 x 10\^3/uL; Platelets >= 75 x 10\^3/uL (within 28 days prior to registration); If there is documented lymphomatous involvement of the bone marrow as assessed by bone marrow biopsy within 90 days prior to registration, participants must have: Platelets >= 50 x 10\^3/uL; Aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (IULN), alanine aminotransferase (ALT) =< 3 x IULN (within 28 days prior to registration) unless due to Gilbert's disease, hemolysis, or lymphomatous involvement of liver; Participants with lymphomatous involvement of the liver must have AST =< 5 x IULN, ALT =< 5 x IULN; Total bilirubin =< 1.5 x IULN (within 28 days prior to registration) unless due to Gilbert's disease, hemolysis, or lymphomatous involvement of liver; Participants with lymphomatous involvement of the liver must have total bilirubin =< 5 x IULN; Participants must have a calculated creatinine clearance >= 30 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to registration; Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better; Participants must have recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia; Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at randomization and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration; Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on the most recent test results obtained within the last year and received suppressive therapy; Participants with a history of hepatitis C virus (HCV) infection must have an undetectable viral load. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 28 days prior to registration; Participants must be able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels; Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System; Participants who can complete the FACT-Lym and PRO-CTCAE forms in English or Spanish must agree to participate in the patient-reported outcome study; Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines; For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and central institutional review board (CIRB) regulations.

Kizáró feltételek: Participants must not have a known prior history of T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute leukemia (T-ALL). Testing is not required for eligibility determination; Participants must not have received prior treatment with tafasitamab and/or lenalidomide; Participants must not have had prior BTK inhibitor or tazemetostat; Participants must not be receiving direct vitamin K inhibitors or strong or moderate CYP3A inhibitors or inducers at the date of registration; Notes: Because the list of these agents is constantly changing, it is important to regularly consult a frequently updated medical reference; Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen; Participants must not be pregnant or nursing and must follow the guidelines according to the lenalidomide Risk Evaluation and Mitigation Strategies (REMS) program. The effects of tazemetostat, zanubrutinib, lenalidomide and tafasitamab, and the combination of these drugs have not been studied on the developing human fetus are the effects are unknown. Individuals who are of reproductive potential must have agreed to use a highly effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential". In addition to routine contraceptive methods, "acceptable contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen; Participants must not have known abnormalities associated with myelodysplastic syndrome (MDS) (e.g., del 5q, chr 7 abn) and myeloproliferative neoplasms (MPN) (e.g., JAK2 V617F) observed in cytogenetic testing and deoxyribonucleic acid (DNA) sequencing. Testing is not required for eligibility determination; Participants must not be a candidate based on investigator assessment to receive autologous stem cell transplant (ASCT) or must have declined ASCT. Participants who had disease progression after stem cell transplant or cellular therapy (such as chimeric antigen receptor (CAR) T-cell) are eligible; Participants must not have any known allergy or reaction to any component of tafasitamab, lenalidomide, tazemetostat or zanubrutinib; Participants must not have active lymphomatous involvement of the central nervous system (CNS) because the treatments used in this study are not effective to sufficiently penetrate the blood brain barrier.

ClinicalTrials.gov NCT05890352